Narikazu Boku

29.4k citations
541 papers · 15.3k indexed · 5 hit papers · h-index 61
    • Gastrointestinal Tumor Research and Treatment 99
    • Gastric Cancer Management and Outcomes 315
    • Metastasis and carcinoma case studies 71
    • Lung Cancer Treatments and Mutations 50
  • Oncology top 0.1%
    • Colorectal Cancer Treatments and Studies 209
    • Cancer Treatment and Pharmacology 66
  • Surgery top 0.2%
    • Cholangiocarcinoma and Gallbladder Cancer Studies 62
    • Esophageal Cancer Research and Treatment 61
  • Hepatology top 1%

Narikazu Boku

507 papers receiving 15.0k citations

Hit Papers

Phase III, randomised trial of avelumab ...3722009202620142020200400600

Peers

Narikazu Boku
Comparison fields: 5 of 125
  • Gastroenterology 3.1k
  • Pulmonary and Respiratory Medicine 10.0k
  • Oncology 8.1k
  • Surgery 6.3k
  • Hepatology 565
Replace Stephen Falk with:
Stephen Falk United Kingdom
Giuseppe Aprile Italy
David P. Kelsen United States
Toshiharu Yamaguchi Japan
Timothy Iveson United Kingdom
Kenichi Sugihara Japan
Antoine Adenis France
Won Ki Kang South Korea
Dirk Arnold Germany
Joon Oh Park South Korea
Narikazu Boku relative to Stephen Falk United Kingdom Stephen Falk's profile →
Citations per field
00.5×4.3×
Stephen Falk · 1×
Citations per year

Countries citing papers authored by Narikazu Boku

Since Specialization
Citations

This map shows the geographic impact of Narikazu Boku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narikazu Boku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narikazu Boku more than expected).

Fields of papers citing papers by Narikazu Boku

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narikazu Boku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narikazu Boku. The network helps show where Narikazu Boku may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Narikazu Boku, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Narikazu Boku Line = papers co-authored together Narikazu Boku links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20252
2 20253
3 20241
4 20240
5 20232
6 20231
7 20221
8 202211
9 202212
10 202210
11 202161
12 20210
13 20212
14 20207
15 202011
16 20203
17 202030
18 201654
19
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
20126
20 201139

About Narikazu Boku

Narikazu Boku is a scholar working on Gastroenterology, Oncology and Pulmonary and Respiratory Medicine, having authored 541 papers that have together received 15.3k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (315 papers), Colorectal Cancer Treatments and Studies (209 papers), Gastrointestinal Tumor Research and Treatment (99 papers), Metastasis and carcinoma case studies (71 papers), Cancer Treatment and Pharmacology (66 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (62 papers), Esophageal Cancer Research and Treatment (61 papers) and Lung Cancer Treatments and Mutations (50 papers). The work is most often cited by research in Gastroenterology (3.1k citations), Pulmonary and Respiratory Medicine (10.0k citations) and Oncology (8.1k citations). Narikazu Boku has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Atsushi Ohtsu, Shigeaki Yoshida, Manabu Muto, Kuniaki Shirao, Kei Muro, Shuichi Hironaka, Ichinosuke Hyodo, Kensei Yamaguchi, Haruhiko Fukuda and Hiroshi Saito. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026